Showing 1,901 - 1,920 results of 230,837 for search '(( 10 ((mean decrease) OR (a decrease)) ) OR ( 5 ((mean decrease) OR (a decrease)) ))', query time: 2.30s Refine Results
  1. 1901

    Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  2. 1902

    Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…These values significantly decreased in the first postoperative year to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0, and 3.1 ± 2.8; in the second year to 2.1 ± 2.8, 0.4 ± 1.0, 0.0, 0.1 ± 0.3, and 2.6 ± 2.8; and in the third year to 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 (Kruskal–Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g007" target="_blank">Fig 7</a>). …”
  3. 1903

    Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  4. 1904

    Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…In the non-recurrence group, CRT improved from 482.5 ± 112.8 to 294.7 ± 65.3, 302.0 ± 68.0, 284.7 ± 55.4, 285.3 ± 70.2, 265.2 ± 65.0, and 266.1 ± 78.2 μm at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g006" target="_blank">Fig 6</a>).…”
  5. 1905
  6. 1906

    Significant decrease of SMAD4 protein in DBA iPSCs. by Jingping Ge (636557)

    Published 2015
    “…A) Slight decrease of mRNA level of <i>SMAD4</i> in the DBA iPSCs with <i>RPS19</i> or <i>RPL5</i> mutations. …”
  7. 1907
  8. 1908
  9. 1909
  10. 1910
  11. 1911
  12. 1912
  13. 1913

    Changes in neural activity were decreased in animals pre-exposed to 5-HT and <i>mod-1</i> mutants when the worms switched their locomotive direction. by Haruka Mori (8082215)

    Published 2019
    “…<p>(A–F) the neural activity of the RID changes during the transition periods from backward to forward locomotion (A–C) and from forward to backward locomotion (D–F) in the mock (A: p = 1.5 × 10<sup>−5</sup>; D: p = 5.5 × 10<sup>−13</sup>), 5-HT exposed (B: p = 0.092; E: p = 0.79), and <i>mod-1</i> mutant (C: p = 0.081; F: p = 0.93) groups. …”
  14. 1914
  15. 1915
  16. 1916
  17. 1917
  18. 1918
  19. 1919

    Pretreatment with terazosin (0.5, 1 mg/kg) reversed the decrease in EEG amplitude produced by modafinil (90 mg/kg, i.p.). by Chang-Rui Chen (467755)

    Published 2013
    “…The increase in EEG amplitude may be interpreted as synchronization and a decrease in EEG can be interpreted as a desynchronization. …”
  20. 1920

    Decreased capillary density and cardiac fibrosis in <i>Nkx2.5-Cre/Foxm1<sup>fl/fl</sup></i> heart. by Craig Bolte (299486)

    Published 2013
    “…Capillary density was decreased in <i>Nkx2.5-Cre/Foxm1<sup>fl/fl</sup></i> hearts at P11 (A–B, I), while coronary vessel formation was not altered (C–D). …”